MeSH tree: E01.789.800
Results from an early-stage clinical trial, published in Nature Communications, showed encouraging outcomes among patients with newly diagnosed cancer whose tumors had spread to distant organs. Most strikingly, one patient ...
Aug 28, 2026
0
19
Results of the NRG Oncology NRG-GU005 clinical study comparing stereotactic body radiation therapy (SBRT) with moderately hypofractionated intensity-modulated radiation therapy (MH-IMRT) for patients with localized intermediate-risk ...
Aug 25, 2026
0
7
Combining chemotherapy with immunotherapy before surgery for head and neck cancer is associated with significantly greater reductions in tumor size than immunotherapy alone, according to a study published online Aug. 13 in ...
Aug 21, 2026
0
3
The cost-effectiveness of the immunotherapy drug pembrolizumab for patients with locally advanced head and neck squamous cell carcinoma may depend on biomarker results, according to a new study.
Aug 10, 2026
0
5
Patients with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer experienced a 58% reduction in the risk of disease progression or death when treated with atezolizumab ...
Jul 30, 2026
0
8
A combination of two immunotherapy drugs showed encouraging activity when added to standard chemotherapy given before surgery for patients with high-risk, early-stage HER2-negative breast cancer, according to Phase II clinical ...
Jul 30, 2026
0
11
Women suffering from pelvic organ prolapse might be best served by surgery that preserves their uterus rather than removing it, a landmark clinical trial reports.
Jul 21, 2026
0
4
For patients with newly diagnosed multiple myeloma not undergoing an autologous stem cell transplant, indefinite lenalidomide maintenance has long been standard care despite limited evidence to guide the optimal duration ...
Jul 16, 2026
0
8
Results of the Phase III COMPETE clinical trial show that the targeted radiotherapeutic agent [177Lu]Lu-edotreotide significantly prolonged progression-free survival in patients with metastatic gastroenteropancreatic neuroendocrine ...
Jul 7, 2026
0
6
For patients with clear-cell renal cell carcinoma, pembrolizumab-belzutifan yields significantly higher disease-free survival, according to a study published in the July 2 issue of the New England Journal of Medicine.
Jul 6, 2026
0
5
